Testing a new medicine for advanced solid tumors
Part of Cancer clinical trials.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old, and you can sign informed consent
- You have a confirmed advanced solid tumor (like breast, lung, stomach, liver, or colon cancer) that has stopped responding to standard treatment or has no good standard option
- You have at least one tumor spot that can be measured on CT or MRI for follow-up
- You must be at least 4 weeks past your last major treatment (and 2 weeks past hormone/endocrine therapy) and your side effects are mostly gone
- Blood and organ tests must be strong enough (bone marrow, liver, kidney)—the study lists specific threshold values
- You must have an ECOG performance status of 0 or 1 (you can do daily activities with little or no help) and have at least 3 months expected survival
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.
This trial tests a new drug, Hemay181, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can shrink tumors and how safe it is.
This study tests a new experimental drug called Hemay5087 to see if it is safe and effective in treating advanced cancers that have not responded to standard treatments. Researchers will monitor your health closely and measure whether the cancer shrinks.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.